PhRMA says FDA will get money it can spend only on hiring and keeping staff, to restore reviewer levels after the HHS layoffs ...
WHO releases preeclampsia roadmap; Comanche, DiaMedica, Avilar & ProFound developing treatments; Eli Lilly exploring the ...
Biohaven licenses pan-IgG degraders to Ono for $80M; UK pulls Ixchiq; ADC raises $86.6M; BMS Zenbexus Phase 3 win; Pfizer ...
IPOs on Nasdaq, backed by Eli Lilly, focusing on Treg science for autoimmune disorders. Pipeline includes TRB-061 and a CD30 agonist for IBD.
Petrelintide reduced patients’ average body weight by up to 9.2%, compared to 2.0% among those who received placebo.
Roche partners with Hangzhou-based Defand Therapeutics in a ~$1B deal, under $10M upfront, to develop molecular glue ...
Grindr acquires Freddie's parent for $250M to expand into HIV prevention (PrEP). The company will combine that with ED drugs and GLP-1s under new Grindr Health brand.
General Medicine raises a $120M Series B led by a16z, betting its 2,900-product catalog can serve AI shopping agents as well as people.
Plus news about Denali, Nuvectis Pharma, Graph Therapeutics, GondolaBio and the Novo Nordisk Foundation. 🔗 Eli Lilly’s alliance with BioArctic: The Indianapolis drug giant will ...
Chan Zuckerberg Biohub launches $1.8B Virtual Biology Initiative with Meta, Google DeepMind, Isomorphic Labs, DOE, and NIH to ...
PhRMA sued CMS over GLOBE, the Trump admin's Medicare Part B demo tying drug prices to overseas rates, calling it unlawful.
Ultragenyx sells a rare pediatric disease PRV for $210M, one of 2026's priciest voucher deals, and plans to monetize a second ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results